Stocks
Recursion Projects 2028 Runway, Holds 2026 Expenses Below $390M
Recursion Pharmaceuticals projects its operational runway into early 2028 while committing to keep 2026 cash operating expenses under $390 million, driven by...
#pharmaceuticals 29 articles
Markets
Pfizer Stock: Is Its ‘Dead Money’ Tag Misleading?
Pfizer shares have fallen over 50% from their 2021 high, leading many to label it "dead money." However, a closer look reveals...
Stocks
Quantum BioPharma Taps Senergy, King Tide for Investor Outreach
Quantum BioPharma Ltd. has engaged Senergy Communications Capital Inc. and King Tide Media LLC for a one-month contract to bolster investor awareness...
Markets
Eli Lilly’s Diversification Offers Stronger Investment Case
Beyond its weight-loss drug success, Eli Lilly's robust pipeline across oncology, immunology, and neuroscience presents a compelling investment thesis.
Stocks
Eli Lilly Nears $2B-Plus Kelonia Deal for Cancer Pipeline
Eli Lilly is in advanced talks to acquire Kelonia Therapeutics for over $2 billion, aiming to expand its cancer pipeline, The Wall...
Markets
Bristol Myers Squibb: A Value Contender in Pharma
Bristol Myers Squibb (BMY) shows compelling value with a low forward P/E and a 4.2% dividend yield, despite concerns over legacy drug...
Stocks
Organon Shares Soar 23% on Sun Pharma Reports, Best Intraday Rally
Organon (OGN) stock surged approximately 23% on Friday, driven by media reports from India indicating a development with generic drugmaker Sun Pharmaceutical....
Stocks
Sanofi’s Lunsekimig Achieves Phase 2 Endpoints in Asthma, CRSwNP Studies
Sanofi's novel bispecific Nanobody VHH, lunsekimig, met primary and key secondary endpoints in its Phase 2 trials for asthma and CRSwNP, the...
Stocks
Neurocrine Nears $2.5B-Plus Soleno Acquisition
Neurocrine Biosciences is in advanced talks to acquire Soleno Therapeutics for over $2.5 billion, potentially valuing Soleno shares in the low-to-mid $50s,...